Company Filing History:
9 out of 523 
4 out of 2,170 
2 out of 20 
Years Active: 1988-2008
Title: Innovations of Heinrich Josef Schostarez in Alzheimer’s Disease Treatment
Introduction: Heinrich Josef Schostarez is an accomplished inventor based in Portage, MI, known for his significant contributions in the field of pharmaceuticals, particularly focusing on compounds that aim to treat Alzheimer’s disease. With a prolific portfolio of 20 patents, Schostarez has demonstrated a commitment to advancing medical science and improving patient outcomes.
Latest Patents: Among his most recent inventions are two key patents that show promise in the treatment of Alzheimer’s disease. The first patent involves amine 1,2- and 1,3-diol compounds, which are disclosed as useful in combating Alzheimer's disease and similar conditions. These compounds inhibit the beta-secretase enzyme, which is crucial in reducing A beta peptide formation in mammals, thereby playing a role in the progression of Alzheimer's disease. His second patent details statine derivatives that also target the beta-secretase enzyme for the treatment of Alzheimer's, emphasizing the importance of these compounds in pharmaceutical compositions designed to mitigate the effects of the disease.
Career Highlights: Schostarez has made significant strides in pharmaceutical research through his work at reputable companies such as Pharmacia & Upjohn Company and The Upjohn Company. These positions allowed him to engage deeply with innovative research and development processes, fostering his ability to create impactful inventions in the industry.
Collaborations: Throughout his career, Heinrich has collaborated with notable professionals in the field, including Robert Alan Chrusciel and Scott D Larsen. These partnerships have contributed to advancing research initiatives and have likely provided a robust collaborative framework for developing new treatment options.
Conclusion: Heinrich Josef Schostarez exemplifies the spirit of innovation in the pharmaceutical industry with his focus on Alzheimer's disease treatment. His dedication to researching and developing compounds that inhibit critical enzymes offers hope for effective therapies and contributes to the broader fight against neurodegenerative diseases. With a strong foundation of patents and a noteworthy career, Schostarez continues to influence the landscape of pharmaceutical innovation.